| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients.
|
J Clin Oncol
|
2003
|
4.15
|
|
2
|
Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study.
|
J Infect Dis
|
2012
|
2.43
|
|
3
|
Frequency, determinants and consequences of delayed access to care for HIV infection in France.
|
Antivir Ther
|
2007
|
1.83
|
|
4
|
The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: evidence from the MANIF2000 cohort study.
|
Addiction
|
2008
|
1.76
|
|
5
|
Retention in opioid substitution treatment: a major predictor of long-term virological success for HIV-infected injection drug users receiving antiretroviral treatment.
|
Clin Infect Dis
|
2009
|
1.65
|
|
6
|
Primary liver cancer is more aggressive in HIV-HCV coinfection than in HCV infection. A prospective study (ANRS CO13 Hepavih and CO12 Cirvir).
|
Clin Res Hepatol Gastroenterol
|
2011
|
1.62
|
|
7
|
Relapse of hepatitis C virus after 14 months of sustained virological response following pegylated-interferon alpha plus ribavirin therapy in a human immunodeficiency virus type 1 infected patient.
|
J Clin Virol
|
2013
|
1.44
|
|
8
|
Efficacy and tolerability of a nucleoside reverse transcriptase inhibitor-sparing combination of lopinavir/ritonavir and efavirenz in HIV-1-infected patients.
|
J Acquir Immune Defic Syndr
|
2005
|
1.29
|
|
9
|
A large French prospective cohort of HIV-infected patients: the Nadis Cohort.
|
HIV Med
|
2009
|
1.29
|
|
10
|
Risk factors of chronic kidney disease in HIV-infected patients.
|
Clin J Am Soc Nephrol
|
2011
|
1.21
|
|
11
|
Genomic and phylogenetic analysis of hepatitis C virus isolates: a survey of 535 strains circulating in southern France.
|
J Med Virol
|
2003
|
1.16
|
|
12
|
Therapeutic drug monitoring of lopinavir/ritonavir given alone or with a non-nucleoside reverse transcriptase inhibitor.
|
Br J Clin Pharmacol
|
2004
|
1.08
|
|
13
|
HIV-associated Hodgkin lymphoma during the first months on combination antiretroviral therapy.
|
Blood
|
2011
|
1.02
|
|
14
|
The spectrum of malignancies in HIV-infected patients in 2006 in France: the ONCOVIH study.
|
Int J Cancer
|
2011
|
1.00
|
|
15
|
Effects of antiretroviral drug combinations on the differentiation of adipocytes.
|
AIDS
|
2002
|
0.99
|
|
16
|
Hepatitis E virus infection in patients infected with the human immunodeficiency virus.
|
J Med Virol
|
2011
|
0.99
|
|
17
|
Minimal effect of MDR1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of indinavir in HIV-infected patients.
|
Br J Clin Pharmacol
|
2007
|
0.98
|
|
18
|
Human immunodeficiency virus infection and non-small cell lung cancer: survival and toxicity of antineoplastic chemotherapy in a cohort study.
|
J Thorac Oncol
|
2011
|
0.97
|
|
19
|
High indinavir Cmin is associated with higher toxicity in patients on indinavir-ritonavir 800/100 mg twice-daily regimen.
|
J Acquir Immune Defic Syndr
|
2002
|
0.97
|
|
20
|
Immunogenicity and safety of an HIV-1 lipopeptide vaccine in healthy adults: a phase 2 placebo-controlled ANRS trial.
|
AIDS
|
2010
|
0.97
|
|
21
|
Cohort Profile: French hospital database on HIV (FHDH-ANRS CO4).
|
Int J Epidemiol
|
2014
|
0.96
|
|
22
|
Simplification therapy with once-daily emtricitabine, didanosine, and efavirenz in HIV-1-infected adults with viral suppression receiving a protease inhibitor-based regimen: a randomized trial.
|
J Infect Dis
|
2005
|
0.93
|
|
23
|
The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13 HEPAVIH): early findings, 2006-2010.
|
BMC Infect Dis
|
2010
|
0.89
|
|
24
|
Risk factors for osteonecrosis in HIV-infected patients: impact of treatment with combination antiretroviral therapy.
|
AIDS
|
2006
|
0.89
|
|
25
|
The genotypic inhibitory quotient: a predictive factor of atazanavir response in HIV-1-infected treatment-experienced patients.
|
J Acquir Immune Defic Syndr
|
2008
|
0.89
|
|
26
|
Impact of hepatitis C virus coinfection on T-cell dynamics in long-term HIV-suppressors under combined antiretroviral therapy.
|
AIDS
|
2015
|
0.88
|
|
27
|
Long-term effects of intermittent interleukin-2 therapy in chronic HIV-infected patients (ANRS 048-079 Trials).
|
AIDS
|
2007
|
0.88
|
|
28
|
Coexistence of the K65R/L74V and/or K65R/T215Y mutations on the same HIV-1 genome.
|
J Clin Virol
|
2006
|
0.86
|
|
29
|
IL-2 therapy: potential impact of the CD4 cell count at initiation on clinical efficacy--results from the ANRS CO4 cohort.
|
J Antimicrob Chemother
|
2010
|
0.84
|
|
30
|
Long-term CD4(+) and CD8(+) T-cell responses induced in HIV-uninfected volunteers following intradermal or intramuscular administration of an HIV-lipopeptide vaccine (ANRS VAC16).
|
Vaccine
|
2013
|
0.84
|
|
31
|
Ribavirin and abacavir drug interaction in HIV-HCV coinfected patients: fact or fiction?
|
AIDS
|
2012
|
0.83
|
|
32
|
Feasibility and efficacy of early lung cancer diagnosis with chest computed tomography in HIV-infected smokers.
|
AIDS
|
2016
|
0.83
|
|
33
|
Cellular immune responses induced with dose-sparing intradermal administration of HIV vaccine to HIV-uninfected volunteers in the ANRS VAC16 trial.
|
PLoS One
|
2007
|
0.81
|
|
34
|
Four year follow-up of simplification therapy with once-daily emtricitabine, didanosine and efavirenz in HIV-infected patients (ALIZE ANRS 099 trial).
|
J Antimicrob Chemother
|
2010
|
0.80
|
|
35
|
Distribution of human papillomavirus genotypes, assessment of HPV 16 and 18 viral load and anal related lesions in HIV positive patients: a cross-sectional analysis.
|
J Med Virol
|
2013
|
0.80
|
|
36
|
Hepatitis C virus NS3 protease genotyping and drug concentration determination during triple therapy with telaprevir or boceprevir for chronic infection with genotype 1 viruses, southeastern France.
|
J Med Virol
|
2014
|
0.80
|
|
37
|
Intensive sequential chemotherapy with hematopoietic growth factor support for non-Hodgkin lymphoma in patients infected with the human immunodeficiency virus.
|
Cancer
|
2004
|
0.79
|
|
38
|
Baseline CD4 cell count and outcome of pegylated interferon plus ribavirin therapy in HIV/hepatitis C virus-coinfected patients.
|
J Acquir Immune Defic Syndr
|
2008
|
0.79
|
|
39
|
Phase IV study of liposomal daunorubicin (DaunoXome) in AIDS-related Kaposi sarcoma.
|
Am J Clin Oncol
|
2002
|
0.79
|
|
40
|
From first-generation hepatitis C virus protease inhibitors to direct-acting antivirals: self-reported symptoms as a warning signal for potential adverse events (ANRS HC26, ANRS HC27 trials).
|
Eur J Gastroenterol Hepatol
|
2016
|
0.78
|
|
41
|
Withdrawal symptoms as a predictor of mortality in patients HIV-infected through drug use and receiving highly active antiretroviral therapy (HAART).
|
Drug Alcohol Depend
|
2008
|
0.78
|
|
42
|
HIV protease inhibitors do not cause the accumulation of prelamin A in PBMCs from patients receiving first line therapy: the ANRS EP45 "aging" study.
|
PLoS One
|
2012
|
0.78
|
|
43
|
HIV-1 infection and first line ART induced differential responses in mitochondria from blood lymphocytes and monocytes: the ANRS EP45 "Aging" study.
|
PLoS One
|
2012
|
0.78
|
|
44
|
Mandibular osteonecrosis and dental exfoliation after trigeminal zoster in an HIV-infected patient: case report and review of the literature.
|
AIDS
|
2014
|
0.77
|
|
45
|
Erythrocyte and plasma ribavirin concentrations in the assessment of early and sustained virological responses to pegylated interferon-alpha 2a and ribavirin in patients coinfected with hepatitis C virus and HIV.
|
J Antimicrob Chemother
|
2012
|
0.76
|
|
46
|
The effects of a maintenance therapy with peg-interferon alpha-2a on liver fibrosis in HIV/HCV co-infected patients: a randomized controlled trial.
|
J Infect
|
2013
|
0.76
|
|
47
|
Intensive chemotherapy with rituximab is safe and effective in AIDS non-Hodgkin's lymphoma.
|
AIDS
|
2003
|
0.75
|
|
48
|
Long-term efficacy and toxicity of abacavir/lamivudine/nevirapine compared to the most prescribed ARV regimens before 2013 in a French Nationwide Cohort Study.
|
Medicine (Baltimore)
|
2016
|
0.75
|
|
49
|
Impact of baseline plasma HIV-1 RNA and time to virological suppression on virological rebound according to first-line antiretroviral regimen.
|
J Antimicrob Chemother
|
2017
|
0.75
|
|
50
|
Frailty in HIV infected people: a new risk factor for bone mineral density loss.
|
AIDS
|
2017
|
0.75
|
|
51
|
Epidemiological and virological features of HBV infection in HIV-2 infected patients living in southeastern France.
|
Eur J Epidemiol
|
2006
|
0.75
|
|
52
|
Pharmacokinetic interaction between lopinavir/r and amprenavir in salvage therapy.
|
J Acquir Immune Defic Syndr
|
2002
|
0.75
|
|
53
|
Use of first-generation HCV protease inhibitors in patients coinfected by HIV and HCV genotype 1.
|
Liver Int
|
2013
|
0.75
|
|
54
|
Estimated glomerular filtration rate but not solute carrier polymorphisms influences anemia in HIV-hepatitis C virus coinfected patients treated with boceprevir or telaprevir-based therapy.
|
AIDS
|
2016
|
0.75
|
|
55
|
Interleukine-2 therapy does not increase the risk of Hodgkin or non-Hodgkin lymphoma in HIV-infected patients: results from FHDH ANRS CO4.
|
J Acquir Immune Defic Syndr
|
2009
|
0.75
|
|
56
|
Pharmacokinetic interaction between maraviroc and etravirine in HIV-infected patients receiving regimens containing both drugs and no ritonavir-boosted protease inhibitor.
|
J Antimicrob Chemother
|
2012
|
0.75
|
|
57
|
Can the "seek, test, treat, and retain" strategy be effective in France?
|
J Acquir Immune Defic Syndr
|
2013
|
0.75
|
|
58
|
Tipranavir in highly antiretroviral treatment-experienced patients: Results from a French prospective cohort.
|
Scand J Infect Dis
|
2011
|
0.75
|
|
59
|
Short article: Fatigue in the long term after HCV treatment in HIV-HCV-coinfected patients: functional limitations persist despite viral clearance in patients exposed to peg-interferon/ribavirin-containing regimens (ANRS CO13-HEPAVIH cohort).
|
Eur J Gastroenterol Hepatol
|
2016
|
0.75
|
|
60
|
[Cancer and HIV].
|
Bull Cancer
|
2014
|
0.75
|